Comparison of peritoneal dialysis and hemodialysis as first renal replacement therapy in patients with end-stage renal disease and diabetes: a systematic review
Tóm tắt
Diabetes has become the most common cause of end-stage renal disease (ESRD) requiring renal replacement therapy (RRT) in most countries around the world. Peritoneal dialysis (PD) is valuable for patients newly requiring RRT because of the preservation of residual renal function (RRF), higher quality of life, and hemodynamic stability in comparison with hemodialysis (HD). A previous systematic review produced conflicting results regarding patient survival. As several advances have been made in therapy for diabetic patients receiving PD, we conducted a systematic review of studies published after 2014 to determine whether incident PD or HD is advantageous for the survival of patients with diabetes.
For this systematic review, the MEDLINE, EMBASE, and CENTRAL databases were searched to identify articles published between February 2014 and August 2017. The quality of studies was assessed using the GRADE approach. Outcomes of interest were all-cause mortality; RRF; major morbid events, including cardiovascular disease (CVD) and infectious disease; and glycemic control. This review was performed using a predefined protocol published in PROSPERO (CRD42018104258).
Sixteen studies were included in this review. All were retrospective observational studies, and the risk of bias, especially failure to adequately control confounding factors, was high. Among them, 15 studies investigated all-cause mortality in diabetic patients initiating PD and HD. Differences favoring HD were observed in nine studies, whereas those favoring PD were observed in two studies. Two studies investigated effects on CVD, and both demonstrated the superiority of incident HD. No study investigated the effect of any other outcome.
In the present systematic review, the risk of death tended to be higher among diabetic patients with ESRD newly initiating RRT with incident PD in comparison with incident HD. However, we could not obtain definitive results reflecting the superiority of PD or HD with regard to patient outcomes because of the severe risk of bias and the heterogeneity of management strategies for diabetic patients receiving dialysis. Further studies are needed to clarify the advantages of PD and HD as RRT for diabetic patients with ESRD.
Từ khóa
Tài liệu tham khảo
Saran R, Robinson B, Abbott KC, Agodoa LYC, Bhave N, Bragg-Gresham J, et al. US renal data system 2017 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2018;71(3S1):S1–676.
Kramer A, Pippias M, Noordzij M, Stel VS, Afentakis N, Ambuhl PM, et al. The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary. Clinical kidney journal. 2018;11(1):108–22.
Masakane I, Taniguchi M, Nakai S, Tsuchida K, Goto S, Wada A, et al. Annual dialysis data report 2015, JSDT Renal Data Registry. Renal Replacement Therapy. 2018;4:19.
Chaudhary K, Sangha H, Khanna R. Peritoneal dialysis first: rationale. Clin J Am Soc Nephrol. 2011;6(2):447–56.
Jain AK, Blake P, Cordy P, Garg AX. Global trends in rates of peritoneal dialysis. J Am Soc Nephrol. 2012;23(3):533–44.
Stack AG. Determinants of modality selection among incident US dialysis patients: results from a national study. J Am Soc Nephrol. 2002;13(5):1279–87.
Korevaar JC, Feith GW, Dekker FW, van Manen JG, Boeschoten EW, Bossuyt PM, et al. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int. 2003;64(6):2222–8.
Couchoud C, Bolignano D, Nistor I, Jager KJ, Heaf J, Heimburger O, et al. Dialysis modality choice in diabetic patients with end-stage kidney disease: a systematic review of the available evidence. Nephrol Dial Transplant. 2015;30(2):310–20.
Moher D, Liberati A, Tetzlaff J, Altman DG. Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine. 2009;6(7):e1000097.
Kim HJ, Park JT, Han SH, Yoo TH, Park HC, Kang SW, et al. The pattern of choosing dialysis modality and related mortality outcomes in Korea: a national population-based study. The Korean journal of internal medicine. 2017;32(4):699–710.
Shen CH, Zheng CM, Kiu KT, Chen HA, Wu CC, Lu KC, et al. Increased risk of atrial fibrillation in end-stage renal disease patients on dialysis: a nationwide, population-based study in Taiwan. Medicine. 2016;95(25):e3933.
Tamayo Isla RA, Ameh OI, Mapiye D, Swanepoel CR, Bello AK, Ratsela AR, et al. Baseline predictors of mortality among predominantly rural-dwelling end-stage renal disease patients on chronic dialysis therapies in Limpopo, South Africa. PLoS One. 2016;11(6):e0156642.
Nesrallah GE, Li L, Suri RS. Comparative effectiveness of home dialysis therapies: a matched cohort study. Canadian journal of kidney health and disease. 2016;3:19.
Lee MJ, Kwon YE, Park KS, Kee YK, Yoon CY, Han IM, et al. Glycemic control modifies difference in mortality risk between hemodialysis and peritoneal dialysis in incident dialysis patients with diabetes: results from a nationwide prospective cohort in Korea. Medicine. 2016;95(11):e3118.
Marshall MR, Polkinghorne KR, Kerr PG, Hawley CM, Agar JW, McDonald SP. Intensive hemodialysis and mortality risk in Australian and New Zealand populations. Am J Kidney Dis. 2016;67(4):617–28.
Wang IK, Liang WM, Lin CL, Liu YL, Chang CT, Yen TH, et al. Impact of dialysis modality on the survival of patients with end-stage renal disease and prior stroke. International urology and nephrology. 2016;48(1):139–47.
Waldum-Grevbo B, Leivestad T, Reisaeter AV, Os I. Impact of initial dialysis modality on mortality: a propensity-matched study. BMC Nephrol. 2015;16:179.
Yang F, Khin LW, Lau T, Chua HR, Vathsala A, Lee E, et al. Hemodialysis versus peritoneal dialysis: a comparison of survival outcomes in South-East Asian patients with end-stage renal disease. PLoS One. 2015;10(10):e0140195.
Kim H, Kim KH, Ahn SV, Kang SW, Yoo TH, Ahn HS, et al. Risk of major cardiovascular events among incident dialysis patients: a Korean national population-based study. International journal of cardiology. 2015;198:95–101.
Marshall MR, Polkinghorne KR, Kerr PG, Agar JW, Hawley CM, McDonald SP. Temporal changes in mortality risk by dialysis modality in the Australian and New Zealand dialysis population. Am J Kidney Dis. 2015;66(3):489–98.
Ryu JH, Kim H, Kim KH, Hann HJ, Ahn HS, Lee S, et al. Improving survival rate of Korean patients initiating dialysis. Yonsei medical journal. 2015;56(3):666–75.
Marshall MR, Walker RC, Polkinghorne KR, Lynn KL. Survival on home dialysis in New Zealand. PLoS One. 2014;9(5):e96847.
Kim H, Kim KH, Park K, Kang SW, Yoo TH, Ahn SV, et al. A population-based approach indicates an overall higher patient mortality with peritoneal dialysis compared to hemodialysis in Korea. Kidney Int. 2014;86(5):991–1000.
Heaf JG, Wehberg S. Relative survival of peritoneal dialysis and haemodialysis patients: effect of cohort and mode of dialysis initiation. PLoS One. 2014;9(3):e90119.
Mircescu G, Stefan G, Garneata L, Mititiuc I, Siriopol D, Covic A. Outcomes of dialytic modalities in a large incident registry cohort from Eastern Europe: the Romanian Renal Registry. International urology and nephrology. 2014;46(2):443–51.
Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002;13(5):1307–20.
Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol. 2001;12(10):2158–62.
Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol. 2000;11(3):556–64.
Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI, Oreopoulos DG. Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int. 2000;20(4):429–38.
Udo A, Goodlad C, Davenport A. Impact of diabetes on extracellular volume status in patients initiating peritoneal dialysis. Am J Nephrol. 2017;46(1):18–25.
Kim JK, Kim YS, Song YR, Kim HJ, Kim SG, Moon SJ. Excessive weight gain during the first year of peritoneal dialysis is associated with inflammation, diabetes mellitus, and a rapid decrease in residual renal function. PLoS One. 2015;10(9):e0139033.
Htay H, Johnson DW, Wiggins KJ, Badve SV, Craig JC, Strippoli GF, et al. Biocompatible dialysis fluids for peritoneal dialysis. The Cochrane database of systematic reviews. 2018;10:CD007554.
Park SH, Nam JY, Han E, Lee YH, Lee BW, Kim BS, et al. Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis. Medicine. 2016;95(32):e4543.
Ito H, Mifune M, Matsuyama E, Furusho M, Omoto T, Shinozaki M, et al. Vildagliptin is effective for glycemic control in diabetic patients undergoing either hemodialysis or peritoneal dialysis. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2013;4(2):321–9.
Duong U, Mehrotra R, Molnar MZ, Noori N, Kovesdy CP, Nissenson AR, et al. Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol. 2011;6(5):1041–8.